Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11605-021-05125-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-region ultrasound-based deep learning for post-neoadjuvant therapy axillary decision support in breast cancer.
EBioMedicine
September 2025
Department of Radiology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, 264000, PR China; Big Data and Artificial Intelligence Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, 264000, PR China. Electronic address:
Number of Examined Lymph Nodes in the Highest Quartile Enhances Staging and Prognosis for Patients with Esophageal Cancer Receiving Neoadjuvant Therapy.
Ann Surg Oncol
September 2025
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Background: The optimal number of examined lymph nodes (ELN) for accurate staging and prognosis for esophageal cancer patients receiving neoadjuvant therapy remains controversial. This study aimed to evaluate the impact of ELN count on pathologic staging and survival outcomes and to develop a predictive model for lymph node positivity in this patient population.
Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and a multicenter cohort.
Neoadjuvant Versus Adjuvant Therapy for Metaplastic Breast Cancer: Insights from the National Cancer Database-Is There a Winning Strategy?
Ann Surg Oncol
September 2025
Department of Surgery,Division of Breast Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: This study analyzed a large national cohort to compare treatment strategies and survival outcomes in metaplastic breast cancer (MtBC), a rare and aggressive subtype with poor treatment response.
Patients And Methods: Adult female patients with MtBC diagnosed between 2006 and 2021 were identified from the National Cancer Database and grouped by chemotherapy sequence (neoadjuvant vs. adjuvant) to evaluate clinical characteristics and survival outcomes.
A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.
Am J Clin Oncol
September 2025
Servicio de Oncología Médica HM CIOCC, Hospital Universitario HM Sanchinarro, Facultad HM de Ciencias de la Salud de la Universidad Camilo José Cela, Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain.
Objectives: To evaluate the association between the KRAS mutational load and the histologic tumor response in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant treatment (NAC) with pegylated liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX).
Methods: This was a multicenter, single-arm, interventional, open-label, phase 2 trial in patients 18 years or older who had histologically or cytologically confirmed PDAC and were candidates for surgery and received neoadjuvant NALIRIFOX. The primary outcome was determination of the association between the KRAS mutational load and the histologic tumor response after chemotherapy.
Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma.
Front Endocrinol (Lausanne)
September 2025
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany.
Introduction: The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially unresectable tumor into a resectable state, optimizing local tumor control and prolonging overall survival.
View Article and Find Full Text PDF